Essential thrombocythemia: a review of the clinical features, diagnostic challenges, and treatment modalities in the era of molecular discovery

Leukemia & Lymphoma
Sarah Chuzi, Brady L Stein

Abstract

Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm that is associated with diminished quality of life, thrombohemorrhagic complications, and transformation to myelofibrosis (MF) and acute leukemia (AML). The important recent discoveries of driver mutations, including the calreticulin gene in addition to JAK2 and MPL, have led to a greater understanding of disease pathogenesis and set the stage for the advent of more sophisticated prognostic, diagnostic, and therapeutic strategies. In this paper we summarize recent studies describing the molecular basis of ET. We review the prognostic importance of establishing a 'true' ET diagnosis, as well as risk factors for the development of adverse outcomes including thrombosis, AML (2% risk at 15 years), and MF (9% risk at 15 years). Finally, we discuss the decision to initiate treatment and assess the quality of evidence supporting the use of established, available therapies as well as novel treatments. Special situations, such as pregnancy, familial ET, and extreme thrombocytosis will also be discussed.

References

Oct 1, 1979·British Journal of Haematology·A ManoharanW R Pitney
Oct 21, 1976·The New England Journal of Medicine·J W AdamsonL Steinmann
Mar 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S CortelazzoT Barbui
Aug 1, 1990·Cancer·P FenauxF Bauters
Apr 27, 1995·The New England Journal of Medicine·S CortelazzoT Barbui
Jan 1, 1997·Seminars in Thrombosis and Hemostasis·U Budde, P J van Genderen
Jan 13, 2001·Mayo Clinic Proceedings·A TefferiH C Hoagland
May 15, 2001·European Journal of Haematology·C A Wright, A Tefferi
Mar 12, 2002·Therapeutic Apheresis : Official Journal of the International Society for Apheresis and the Japanese Society for Apheresis·Anne Greist
Mar 18, 1954·The New England Journal of Medicine·H FANGERH LITCHMAN
May 1, 1960·The American Journal of Medicine·F L OZERW C LEVIN
Jan 9, 2004·The New England Journal of Medicine·Raffaele LandolfiUNKNOWN European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators
Nov 16, 2004·The American Journal of Medicine·Francesco PassamontiMario Lazzarino
Apr 29, 2005·The New England Journal of Medicine·Robert KralovicsRadek C Skoda
Jul 8, 2005·The New England Journal of Medicine·Claire N HarrisonUNKNOWN United Kingdom Medical Research Council Primary Thrombocythemia 1 Study
Oct 4, 2005·British Journal of Haematology·Alexandra P WolanskyjAyalew Tefferi
Nov 25, 2006·Hematology·Tiziano Barbui, Guido Finazzi
Jan 9, 2008·American Journal of Hematology·Xiaomei MaH Andrew Selinger

❮ Previous
Next ❯

Related Concepts

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.